Search Results - "Clark, Joseph I."

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial by Margolin, Kim, Prof, Ernstoff, Marc S, MD, Hamid, Omid, MD, Lawrence, Donald, MD, McDermott, David, MD, Puzanov, Igor, MD, Wolchok, Jedd D, MD, Clark, Joseph I, Prof, Sznol, Mario, MD, Logan, Theodore F, MD, Richards, Jon, MD, Michener, Tracy, PharmD, Balogh, Agnes, MS, Heller, Kevin N, MD, Hodi, F Stephen, MD

“…Summary Background Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab…”
Get full text

Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective by Abou Elkassem, Asser M, Lo, Simon S, Gunn, Andrew J, Shuch, Brian M, Dewitt-Foy, Molly E, Abouassaly, Robert, Vaidya, Sandeep S, Clark, Joseph I, Louie, Alexander V, Siva, Shankar, Grosu, Anca-Ligia, Smith, Andrew D

“…With the expansion in cross-sectional imaging over the past few decades, there has been an increase in the number of incidentally detected renal masses and an…”
Get full text

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition by Buchbinder, Elizabeth I, Dutcher, Janice P, Daniels, Gregory A, Curti, Brendan D, Patel, Sapna P, Holtan, Shernan G, Miletello, Gerald P, Fishman, Mayer N, Gonzalez, Rene, Clark, Joseph I, Richart, John M, Lao, Christopher D, Tykodi, Scott S, Silk, Ann W, McDermott, David F

“…Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies…”
Get full text

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study by Cohen, Ezra EW, Dr, Davis, Darren W, PhD, Karrison, Theodore G, PhD, Seiwert, Tanguy Y, MD, Wong, Stuart J, MD, Nattam, Sreenivasa, MD, Kozloff, Mark F, MD, Clark, Joseph I, MD, Yan, Duen-Hwa, PhD, Liu, Wen, MD, Pierce, Carolyn, BA, Dancey, Janet E, MD, Stenson, Kerstin, MD, Blair, Elizabeth, MD, Dekker, Allison, BSN, Vokes, Everett E, Prof

“…Summary Background Epidermal growth factor receptor (EGFR) is a validated target in squamous-cell carcinoma of the head and neck, but in patients with…”
Get full text

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma by McDermott, David F, Regan, Meredith M, Clark, Joseph I, Flaherty, Lawrence E, Weiss, Geoffery R, Logan, Theodore F, Kirkwood, John M, Gordon, Michael S, Sosman, Jeffrey A, Ernstoff, Marc S, Tretter, Christopher P G, Urba, Walter J, Smith, John W, Margolin, Kim A, Mier, James W, Gollob, Jared A, Dutcher, Janice P, Atkins, Michael B

“…The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN)…”
Get full text

Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317 by GORDON, Michael S, HUSSEY, Michael, CRAWFORD, David, NAGLE, Raymond B, LARA, Primo N, MACK, Philip C, DUTCHER, Janice, SAMLOWSKI, Wolfram, CLARK, Joseph I, QUINN, David I, PAN, Chong-Xian

“…Patients with advanced papillary renal cell cancer (pRCC) have poor survival after systemic therapy; the reported median survival time is 7 to 17 months. In…”
Get full text

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 by Sullivan, Ryan J, Atkins, Michael B, Kirkwood, John M, Agarwala, Sanjiv S, Clark, Joseph I, Ernstoff, Marc S, Fecher, Leslie, Gajewski, Thomas F, Gastman, Brian, Lawson, David H, Lutzky, Jose, McDermott, David F, Margolin, Kim A, Mehnert, Janice M, Pavlick, Anna C, Richards, Jon M, Rubin, Krista M, Sharfman, William, Silverstein, Steven, Slingluff, Jr, Craig L, Sondak, Vernon K, Tarhini, Ahmad A, Thompson, John A, Urba, Walter J, White, Richard L, Whitman, Eric D, Hodi, F Stephen, Kaufman, Howard L

“…Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical…”
Get full text

Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer by Almand, Bond, Clark, Joseph I, Nikitina, Ekaterina, van Beynen, James, English, Nicholas R, Knight, Stella C, Carbone, David P, Gabrilovich, Dmitry I

“…Defective dendritic cell (DC) function caused by abnormal differentiation of these cells is an important mechanism of tumor escape from immune system control…”
Get full text

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma by Sosman, Jeffrey A, Carrillo, Carole, Urba, Walter J, Flaherty, Lawrence, Atkins, Michael B, Clark, Joseph I, Dutcher, Janet, Margolin, Kim A, Mier, James, Gollob, Jarod, Kirkwood, John M, Panka, David J, Crosby, Nancy A, O'Boyle, Kevin, LaFleur, Bonnie, Ernstoff, Marc S

“…High-dose interleukin-2 (IL-2) induces responses in 15% to 20% of patients with advanced melanoma; 5% to 8% are durable complete responses (CRs). The…”
Get full text

Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 by ALBAIN, Kathy S, CROWLEY, John J, TURRISI, Andrew T, GANDARA, David R, FARRAR, William B, CLARK, Joseph I, BEASLEY, Kristie R, LIVINGSTON, Robert B

“…There are no published survival data after chemoradiotherapy (chemoRT) in pathologically documented stage IIIB non-small-cell lung cancer. Studies of…”
Get full text

Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report by Clark, Joseph I, Bufalino, Shams, Singh, Shruti, Borys, Ewa

“…The treatment options for metastatic malignant melanoma have drastically changed recently,including the increased use of immunotherapeutic agents that offer…”
Get full text

Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial by CLARK, Joseph I, ATKINS, Michael B, WEISS, Geoffrey R, REDMAN, Bruce G, TRETTER, Christopher P. G, MCDERMOTT, David, SMITH, John W, GORDON, Michael S, MARGOLIN, Kim A, URBA, Walter J, CREECH, Steven, FIGLIN, Robert A, DUTCHER, Janice P, FLAHERTY, Larry, SOSMAN, Jeffrey A, LOGAN, Theodore F, WHITE, Richard

“…This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell…”
Get full text

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma by Buchbinder, Elizabeth I., Gunturi, Anasuya, Perritt, Jessica, Dutcher, Janice, Aung, Sandra, Kaufman, Howard L., Ernstoff, Marc S., Miletello, Girald P., Curti, Brendan D., Daniels, Gregory A., Patel, Sapna P., Kirkwood, John M., Hallmeyer, Sigrun, Clark, Joseph I., Gonzalez, Rene, Richart, John M., Lutzky, Joe, Morse, Michael A., Sullivan, Ryan J., McDermott, David F.

“…BackgroundHigh dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade…”
Get full text

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma by Clark, Joseph I, Singh, Jatinder, Ernstoff, Marc S, Lao, Christopher D, Flaherty, Lawrence E, Logan, Theodore F, Curti, Brendan, Agarwala, Sanjiv S, Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L, Aung, Sandra, Lawson, David H

“…Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an…”
Get full text

HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells by Moore, Tamson V., Scurti, Gina M., DeJong, Matthew, Wang, Siao-Yi, Dalheim, Annika V., Wagner, Courtney R., Hutchens, Kelli A., Speiser, Jodi J., Godellas, Constantine V., Fountain, Chris, Fleser, Jessica, Moudgil, Tarsem, Thomas, Mallory, Murray, David, Curti, Brendan D., Clark, Joseph I., Fox, Bernard A., Nishimura, Michael I.

“…T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated…”
Get full text

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer by Margolin, Kim, Atkins, Michael B, Dutcher, Janice P, Ernstoff, Marc S, Smith, 2nd, John W, Clark, Joseph I, Baar, Joseph, Sosman, Jeffrey, Weber, Jeffrey, Lathia, Chetan, Brunetti, Janice, Cihon, Frank, Schwartz, Brian

“…Purpose: BAY 50-4798 is an analogue of interleukin-2 that selectively activates T cells over natural killer cells. This phase I study was designed to determine…”
Get full text

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma by Hodi, F. Stephen, O'Day, Steven J, McDermott, David F, Weber, Robert W, Weber, Jeffrey S, Sosman, Jeffrey A, Haanen, John B, Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C, Akerley, Wallace, van den Eertwegh, Alfons J.M, Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M, Linette, Gerald P, Hogg, David, Ottensmeier, Christian H, Lebbé, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I, Wolchok, Jedd D, Tian, Jason, Yellin, Michael J, Nichol, Geoffrey M, Hoos, Axel, Urba, Walter J

“…The authors treated 676 patients with metastatic melanoma with an antibody to CTLA-4 (ipilimumab), the antibody plus a gp100 vaccine, or the vaccine alone…”
Get full text

Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients? by Patel, Hiten D, Clark, Joseph I, Flanigan, Robert C

Get full text

Metastatic juxtaglomerular cell tumor in a 52-year-old man by XIUZHEN DUAN, BRUNEVAL, Patrick, HAMMADEH, Rasheed, FRESCO, Raoul, EBLE, John N, CLARK, Joseph I, VIGNESWARAN, Wickii T, FLANIGAN, Robert C, PICKEN, Maria M

“…Juxtaglomerular cell tumor is a rare renal neoplasm arising from the juxtaglomerular apparatus. Approximately 70 cases have been reported in the English…”
Get full text

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial by Algazi, Alain P., Othus, Megan, Daud, Adil I., Lo, Roger S., Mehnert, Janice M., Truong, Thach-Giao, Conry, Robert, Kendra, Kari, Doolittle, Gary C., Clark, Joseph I., Messino, Michael J., Moore, Dennis F., Lao, Christopher, Faller, Bryan A., Govindarajan, Rangaswamy, Harker-Murray, Amy, Dreisbach, Luke, Moon, James, Grossmann, Kenneth F., Ribas, Antoni

“…Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAF V600 in melanoma 1 , 2 . We…”
Get full text